- Home
- ZDAI vs LYRA Comparison
ZDAI vs LYRA Comparison
Compare ZDAI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDAI
- LYRA
- Stock Information
- Founded
- ZDAI 2022
- LYRA 2005
- Country
- ZDAI Hong Kong
- LYRA United States
- Employees
- ZDAI N/A
- LYRA N/A
- Industry
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- LYRA Medical/Dental Instruments
- Sector
- ZDAI Consumer Discretionary
- LYRA Health Care
- Exchange
- ZDAI Nasdaq
- LYRA Nasdaq
- Market Cap
- ZDAI 13.5M
- LYRA 15.0M
- IPO Year
- ZDAI 2024
- LYRA 2020
- Fundamental
- Price
- ZDAI $0.53
- LYRA $7.05
- Analyst Decision
- ZDAI
- LYRA Buy
- Analyst Count
- ZDAI 0
- LYRA 2
- Target Price
- ZDAI N/A
- LYRA $16.00
- AVG Volume (30 Days)
- ZDAI 69.7K
- LYRA 28.3K
- Earning Date
- ZDAI 08-29-2025
- LYRA 08-12-2025
- Dividend Yield
- ZDAI N/A
- LYRA N/A
- EPS Growth
- ZDAI N/A
- LYRA N/A
- EPS
- ZDAI N/A
- LYRA N/A
- Revenue
- ZDAI $19,275,673.00
- LYRA $770,000.00
- Revenue This Year
- ZDAI N/A
- LYRA N/A
- Revenue Next Year
- ZDAI N/A
- LYRA $139.18
- P/E Ratio
- ZDAI N/A
- LYRA N/A
- Revenue Growth
- ZDAI 56.11
- LYRA N/A
- 52 Week Low
- ZDAI $0.37
- LYRA $3.81
- 52 Week High
- ZDAI $107.36
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- ZDAI N/A
- LYRA 41.94
- Support Level
- ZDAI N/A
- LYRA $6.51
- Resistance Level
- ZDAI N/A
- LYRA $7.57
- Average True Range (ATR)
- ZDAI 0.00
- LYRA 0.55
- MACD
- ZDAI 0.00
- LYRA 0.14
- Stochastic Oscillator
- ZDAI 0.00
- LYRA 47.71
About ZDAI Primega Group Holdings Limited Ordinary Shares
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.